Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Tablets in Subjects With Severe Alopecia Areata
In the register
The register attaches this trial to VC005 (Jiangsu Vcare Pharmaceutical), currently at “Phase 2” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- Phase 2
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
- Participants (registry)
- 120
- Start
- August 2026
- Primary completion
- December 2028 (planned)
- Study completion
- December 2028 (planned)
- Last registry update
- August 2026
- Countries
- China
Conditions studied: Alopecia Areata
Interventions: Drug: VC005 tablets, VC005 tablets, VC005 placebo tablets
Other trials of VC005
A Phase I Study of VC005 Tablets in Adolescent Subjects With Severe Alopecia Areata
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.